751-1 Efficacy of Tranilast on Restenosis After Coronary Angioplasty: is There Any Rebound Phenomenon After Ceasing Tranilast at 3 Months?

Ueda, Kinzo; Tamai, Hideo; Hsu, Yung-Sheng; Ono, Shinji; Tanaka, Shōzō; Kosuga, Kunihiko; Okada, Masaharu; Myou-U, Wang; Motohara, Seiichiro; Uehata, Hiromu

doi:10.1016/0735-1097(95)92396-m

Cited by 14 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a small, nonrandomized trial using a historical control group, tranilast 600 mg/day for 3 months was reported to reduce restenosis rates significantly at both 3 and 6 months after PTCA [27]. It was also found to reduce restenosis rates at 3 and 6 months after directional coronary atherectomy in a casecontrol study of 192 patients [28].…”

Section: Tranilastmentioning

confidence: 95%

Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature

Schainfeld

2002

Cathet Cardio Intervent

View full text Add to dashboard Cite

Despite the availability of antiplatelet and antithrombotic therapies, recent advances in catheter and stent technology and improved operator skill, restenosis remains the most frequent problem associated with percutaneous and surgical revascularization interventions for both coronary and peripheral arterial disease. Prevention of restenosis in the coronary vasculature has been demonstrated with cilostazol, trapidil, probucol, tranilast, nitric oxide donors, and clopidogrel. Given the similarities in revascularization procedures and in the pathophysiology of restenosis, it is possible that these results may be extrapolated to the setting of restenosis in the peripheral vasculature, making trials with these agents imperative. Several new agents have shown promising preliminary results for the prevention of restenosis in the peripheral vasculature, including cilostazol, low-molecular-weight heparins, and elastase. Several nonpharmacologic treatment modalities are also under study to prevent peripheral and coronary restenosis and have shown favorable initial results. These include endovascular radiation brachytherapy, arterial gene therapy, photoangioplasty, and several novel treatment delivery systems.

show abstract